
About Nektar Therapeutics (India) Private Limited
Data last updated:
Nektar Therapeutics (India) Private Limited is a foreign private limited company based in Hyderabad, Telangana, India, a subsidiary of Nektar Therapeutics, Usa. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 16 May 2005 and has been in existence for over 21 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24239TG2005FTC046253. The company has 3 GST registrations on record, none of which is active.
The company has an authorised share capital of ₹30 Cr and a paid-up capital of ₹29.39 Cr. It is led by directors including Mark Andrew Wilson and Uday Chandra Yemmanuru.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Hyderabad, Telangana.
As per the financials filed for FY 2025, the company reported a revenue of ₹3.39 Cr, a decline of 8% compared to the previous year. For the same year it recorded a net profit of ₹1.77 Cr (net margin 52.1%) and EBITDA of ₹2.53 Cr (EBITDA margin 74.7%). Revenue has declined at a compounded annual rate (CAGR) of 65% over three years and 46% over five years.
The company has about 3 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Nektar. Court records list 6 cases involving the company, including 5 filed by the company and 1 filed against it; 1 case is pending. The company has 3 deals on record (2 funding rounds, 1 secondary share transfer), with disclosed funding of ₹29.38 Cr; the latest was in April 2009. Its 5 peer companies in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development) are compared by revenue, 1 larger and 4 smaller; the largest is Almora Botanica India Private Limited with revenue of ₹3.4 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website nektar.com.
Company details
CIN history
Nektar Therapeutics (India) has one previous CIN (Corporate Identification Number): U24239AP2005FTC046253. The current CIN is U24239TG2005FTC046253, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239TG2005FTC046253 | Current |
| U24239AP2005FTC046253 | Previous |
Contact details
Nektar Therapeutics (India) Private Limited's registered office is in Hyderabad, Telangana. Its website is nektar.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressPlot No. 105/1 P&T Colony, Tirumalgherry, Hyderabad, Telangana, India – 500015
- IndustryPharma, Pharma Contract R&D
To see the full contact details of Nektar Therapeutics (India) Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Nektar Therapeutics (India) operates one associated brand: Nektar. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Therapeutics for multiple diseases are developed using PEGylation platforms. | nektar.com |
Financials of Nektar Therapeutics (India) Private Limited
FY 2024 filings availableNektar Therapeutics (India) Private Limited reported revenue of ₹3.39 Cr (down 8% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 46% over five years, including a 8% fall in the latest year. EBITDA rose 179% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹2.53 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.77 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 74.7% | ||||
| Net Profit Margin | 52.1% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Nektar Therapeutics (India) Private Limited, buy the company report.
Board of directors of Nektar Therapeutics (India) Private Limited
Nektar Therapeutics (India) has 3 current directors and 20 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mark Andrew Wilson | Director | 19 Mar 2019 | 7 Years 8 Months | Current |
| Uday Chandra Yemmanuru Also directs: Neoen Global Ventures LLP, Afrem Strategic Ventures LLP, Blackorion Services LLP and 5 more | Director | 25 Mar 2024 | 2 Years 7 Months | Current |
| Robert Michael Bacci | Director | 18 Jun 2024 | 2 Years 5 Months | Current |
Peer comparison
Nektar Therapeutics (India) Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Almora Botanica India Private Limited | ₹3.4 Cr (FY 2025) | -38.0% | Bangalore, Karnataka, India | |||
| Nektar Therapeutics (India) Private Limitedthis company | ₹3.39 Cr (FY 2025) | ₹1.77 Cr | 52.1% | -8.0% | 3 | Hyderabad, Telangana, India |
| Vyome Therapeutics Limited | ₹3.35 Cr (FY 2025) | -12.0% | Vadodara, Gujarat, India | |||
| Par Biosciences Private Limited | ₹3.31 Cr (FY 2025) | 1.0% | Chennai, Tamil Nadu, India | |||
| GMK Research Laboratories Private Limited | ₹3.27 Cr (FY 2025) | -20.0% | Secunderabad, Telangana, India | |||
| Mediception Science Private Limited | ₹3.27 Cr (FY 2024) | 35.0% | Gurgaon, Haryana, India |
To see the full peer comparison of Nektar Therapeutics (India) Private Limited, buy the company report.
Auditor
Nektar Therapeutics (India) Private Limited is audited by S. R. BATLIBOI & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S. R. BATLIBOI & ASSOCIATES | FY 2023 | 101049W |
Shareholding
The shareholding of Nektar Therapeutics (India) Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Nektar Therapeutics (India) Private Limited, buy the company report.
Deals & funding
Nektar Therapeutics (India) Private Limited has 3 deals on record (2 funding rounds, 1 secondary share transfer), with disclosed funding of ₹29.38 Cr; the latest was in April 2009.
Deals on record (3 of 3)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Apr 2009 | Funding round | ₹15.69 Cr | Investors: an individual |
| Feb 2007 | Funding round | ₹13.69 Cr | Investors: an individual |
| Jul 2006 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: 2 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Nektar Therapeutics (India) Private Limited has 6 court cases on record: 5 filed by Nektar Therapeutics (India), 1 filed against it. 1 case is pending and 5 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 5 | 1 | 1 |
| Supreme Court | 1 | 0 | 0 |
Cases on record (5 of 6)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, TELANGANA | Court case (ITTA) | Filed against the company by The PR. Commissioner of Income-Tax-4 | Pending |
| High Court, TELANGANA | Writ petition | Filed by the company against Union of India and 5 others | Disposed |
| Supreme Court | Court case (0428-Indirect Taxes Matters : Others) | Filed by the company against Union of India Through Revenue Secretary Ministry of Finance, North Block, New Delhi &Ndash; 110001 , District: New Delhi ,New Delhi , Delhi and 5 others | Disposed |
| High Court of Delhi | Writ petition | Filed by the company against Union of India & Ors. | Disposed |
| High Court, TELANGANA | Writ petition | Filed by the company against Union of India Through Its Secretary, and 2 others | Disposed |
To see the full case history of Nektar Therapeutics (India) Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Nektar Therapeutics (India) Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Nektar Therapeutics (India) Private Limited has a workforce of 3 employees on its EPFO records as of Mar 2024, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2023-24 | 3 |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Nektar Therapeutics (India) Private Limited, buy the company report.
GST
Nektar Therapeutics (India) has 3 GST registrations on record, and all of them have been cancelled or are inactive. Only active GST numbers are listed on this page.
To see the full GST registrations and return filing status of Nektar Therapeutics (India) Private Limited, buy the company report.
Recent activity
Nektar Therapeutics (India) Private Limited has 22 board changes on record since 2007: 3 appointments and 19 cessations. The latest: Robert Michael Bacci ceased to be Additional Director on 29 Sep 2024.
13 earlier events are in the company report.
News
Frequently asked questions
Nektar Therapeutics (India) is an active foreign private limited company based in Hyderabad, Telangana, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 16 May 2005 (21+ years old) and is registered under CIN U24239TG2005FTC046253.
Nektar Therapeutics (India) has 3 current directors:
- Mark Andrew Wilson - Director
- Uday Chandra Yemmanuru - Director
- Robert Michael Bacci - Director
The latest financial statements of Nektar Therapeutics (India) on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
No. Nektar Therapeutics (India) has 3 GST registrations on record and all of them are cancelled or inactive.
The CIN (Corporate Identification Number) of Nektar Therapeutics (India) is U24239TG2005FTC046253. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Nektar Therapeutics (India) has 6 court cases on record: 5 filed by the company and 1 filed against it. 1 is pending. Most are in the high courts.
Nektar Therapeutics (India) was incorporated on 16 May 2005, making it 21+ years old. It is registered with the Registrar of Companies, Hyderabad.
Nektar Therapeutics (India) has 3 deals on record (2 funding rounds, 1 secondary share transfer), with disclosed funding of ₹29.38 Cr; the latest was in April 2009.
The peers of Nektar Therapeutics (India) by revenue are Almora Botanica India Private Limited, Vyome Therapeutics Limited, Par Biosciences Private Limited, GMK Research Laboratories Private Limited, Mediception Science Private Limited, all in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development).
Robert Michael Bacci ceased to be Additional Director on 29 Sep 2024. Uday Chandra Yemmanuru ceased to be Additional Director on 29 Sep 2024. Robert Michael Bacci was appointed as Director on 18 Jun 2024. Nektar Therapeutics (India) has 22 board changes on record in total.
Nektar Therapeutics (India) can be reached through the website nektar.com. Its registered office is in Hyderabad, Telangana, India.

